Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-11-07
2006-11-07
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S242000, C514S256000
Reexamination Certificate
active
07132537
ABSTRACT:
This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
REFERENCES:
patent: 3886136 (1975-05-01), Claeson et al.
patent: 3894995 (1975-07-01), Reske et al.
patent: 4073913 (1978-02-01), Okamoto et al.
patent: 4097472 (1978-06-01), Okamoto et al.
patent: 4144244 (1979-03-01), Brace
patent: 4201863 (1980-05-01), Okamoto et al.
patent: 4304771 (1981-12-01), Suh et al.
patent: 4331570 (1982-05-01), Klemarczyk et al.
patent: 4352751 (1982-10-01), Wieder et al.
patent: 4532342 (1985-07-01), Hoefle et al.
patent: 4622339 (1986-11-01), Lieb et al.
patent: 4705897 (1987-11-01), Alexander
patent: 4761481 (1988-08-01), Hale et al.
patent: 4772607 (1988-09-01), Badger et al.
patent: 4792555 (1988-12-01), McGregor et al.
patent: 5128346 (1992-07-01), Nodzan et al.
patent: 5134123 (1992-07-01), Branca et al.
patent: 5204357 (1993-04-01), Henning et al.
patent: 5236937 (1993-08-01), Bradbury et al.
patent: 5256645 (1993-10-01), Branca et al.
patent: 5268359 (1993-12-01), Harmar et al.
patent: 5317021 (1994-05-01), Kuwamura et al.
patent: 5386033 (1995-01-01), Kusumoto et al.
patent: 5470960 (1995-11-01), Niimura et al.
patent: 5474996 (1995-12-01), Caille et al.
patent: 5491140 (1996-02-01), Bruns et al.
patent: 5492927 (1996-02-01), Gitter et al.
patent: 5506227 (1996-04-01), Zamboni et al.
patent: 5525624 (1996-06-01), Gitter et al.
patent: 5563133 (1996-10-01), Hipskind
patent: 5565568 (1996-10-01), Cho et al.
patent: 5594022 (1997-01-01), Horwell et al.
patent: 5607947 (1997-03-01), Hipskind
patent: 5610176 (1997-03-01), Horwell et al.
patent: 5616562 (1997-04-01), Murphy et al.
patent: 5620987 (1997-04-01), Handa et al.
patent: 5646155 (1997-07-01), Wright
patent: 5652369 (1997-07-01), Handa et al.
patent: 5670499 (1997-09-01), Cho et al.
patent: 5684033 (1997-11-01), Cho et al.
patent: 5693310 (1997-12-01), Gries et al.
patent: 5698710 (1997-12-01), Sisto et al.
patent: 5708173 (1998-01-01), Oku et al.
patent: 5777117 (1998-07-01), Klein et al.
patent: 5994368 (1999-11-01), Oku et al.
patent: 6011066 (2000-01-01), Wang
patent: 6124457 (2000-09-01), DeVries et al.
patent: 6172084 (2001-01-01), Cuny et al.
patent: 6174901 (2001-01-01), Mantlo et al.
patent: 6207667 (2001-03-01), Matsuno et al.
patent: 6291489 (2001-09-01), DeVries et al.
patent: 6329386 (2001-12-01), Mollison
patent: 6369229 (2002-04-01), Head et al.
patent: 6372440 (2002-04-01), Wells
patent: 6376428 (2002-04-01), Sakamoto et al.
patent: 6479484 (2002-11-01), Lan et al.
patent: 6479488 (2002-11-01), Di-Fabio et al.
patent: 6482834 (2002-11-01), Spada et al.
patent: 6495565 (2002-12-01), Duan et al.
patent: 6555684 (2003-04-01), Caldwell et al.
patent: 6559144 (2003-05-01), Diefenbach et al.
patent: 6656958 (2003-12-01), Lin et al.
patent: 6689754 (2004-02-01), Chandrakumar et al.
patent: 6689771 (2004-02-01), Duan et al.
patent: 6750348 (2004-06-01), Bridger et al.
patent: 6765011 (2004-07-01), Sui et al.
patent: 2002/0032206 (2002-03-01), Caldwell et al.
patent: 2002/0052391 (2002-05-01), Di Fabio
patent: 2002/0173507 (2002-11-01), Santora et al.
patent: 2003/0050314 (2003-03-01), Wehner et al.
patent: 2003/0087915 (2003-05-01), Dull et al.
patent: 2003/0096817 (2003-05-01), Green et al.
patent: 2003/0100571 (2003-05-01), Vaccaro et al.
patent: 2003/0109556 (2003-06-01), Mazur et al.
patent: 2003/0130285 (2003-07-01), Myers et al.
patent: 2003/0130289 (2003-07-01), Nuss et al.
patent: 2003/0139427 (2003-07-01), Castelhano et al.
patent: 2003/0158406 (2003-08-01), Cywin et al.
patent: 2003/0171304 (2003-09-01), Holzeman
patent: 2003/0216574 (2003-11-01), Nuss et al.
patent: 2004/0053921 (2004-03-01), Bekkali et al.
patent: 2004/0054186 (2004-03-01), Das et al.
patent: 2004/0063756 (2004-04-01), Collins et al.
patent: 2004/0067980 (2004-04-01), Klingler et al.
patent: 2004/0121998 (2004-06-01), Huang et al.
patent: 2004/0152688 (2004-08-01), Drewry et al.
patent: 676 988 (1991-03-01), None
patent: 2 065 879 (1976-08-01), None
patent: 0778266 (1997-06-01), None
patent: 2 166 316 (1973-08-01), None
patent: 2640970 (1990-06-01), None
patent: 1990 02 025417 (1990-01-01), None
patent: WO 97 16188 (1997-05-01), None
Altura, B.M., and Altura, B.T., “Cardiovascular Risk Factors and Magnesium: Relationships to Atherosclerosis, Ischemic Heart Disease and Hypertension,”Magnes Trace Elem. 1991-92, 10:182-192.
Wells, Ibert C. and Blotcky, Alan J., “Coexisting independent sodium-sensitive and sodium-insensitive mechanisms of genetic hypertension in spontaneously hypertensive rats (SHR),”Can. J. Physiol. Pharmacol. 2001, 79: 779-784
Holvoet, Paul, et al., “Stimulation with a Monoclonal Antibody (mAb4E4) of Scavenger Receptor-mediated Uptake of Chemically Modified Low Density Lipoproteins by THP-1-derived Macrophages Enhances Foam Cell Generation,”J. Clin. Invest., Jan. 1994, 93: 89-98.
Qu, Long, and Stuesse, Sherry, “Influence of Substance P on Carotid Sinus Nerve Baro- and Chemoreceptor Activity in Rabbits,”Peptides. 1990, 11:955-961.
Edvinsson, L., et al., “Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man,”J. Human Hypertension, 1989, 3:267-270.
Faulhaber, H.D., et al., “Substance P in Human Essential Hypertension,”J. Cardiovasc. Pharmacol., 1987, 10(Suppl. 12):S172-S176.
Meyer, P., and Marche, P., “Cell Membrane in Hypertension,”The American Journal of Medical Sciences, Apr. 1988, 295(4):396-399.
Mori, K., et al., “Decreases in Substance P and Vasoactive Intestinal Peptide Concentrations in Plasma of Stroke-Prone Spontaneously Hypertensive Rats,”Jpn. Heart J., Nov. 1993, 34(6):785-794.
Resnick, L.M., et al., “Intracellular free magnesium in erythrocytes of essential hypertension: Relation to blood pressure and serum divalent cations,”Proc. Natl. Acad. Sci. USA, Oct. 1984, 81:6511-6515.
Sanfilippo, J.S., et al., “Amniotic Fluid Levels of Substance P,”The Journal of Reproductive Medicine, Aug. 1992, 37(8):733-736.
Takano, Y., et al., “Substance P immunoreactivity released from rat spinal cord after kainic acid excitation of the ventral medulla oblongata: a correlation with increases in blood pressure,”Brain Research, 1984, 291:168-172.
Frickey, P.H., et al., “Preparation and Characterization of Monoclonal Antibodies to Substance P,”Hybridoma, Nov. 6, 1991, 10:685-694.
Horwell, D.C., “Use of the Chemical Structure of Peptides as the Starting Point to Design Nonpeptide Agonists and Antagonists at Peptide Receptors: Examples with Cholecystokinin and Tachykinina,”Bioorganic&Medicinal Chemistry, 1996, (10):1573-1576.
Mattingly, M.T., et al. “Decreased Cell Membrane Magnesium In Some Essential Hypertension Patients,”Clin. and Exper. Hyper.-Theory and Practice, 1991, 13(1):65-82 (author's reprint enclosed-total of 20 pages).
Theodorsson-Norheim, E., et al., “Neuropeptide K: A Major Tachykinin in Plasma and Tumor Tissues from Carcinold Patients,”Biochemical and Biophysical Research Communications, 1985, 131(1):77-83.
Wells, I.C., et al., “Abnormal magnesium metabolism in two rat models of genetic hypertension,”Can. J. Physiol. Pharmacol., 1992, 70:1225-1229.
Kumar Shailendra
Magnesium Diagnostics, Inc.
Morris Nancy T.
Stinson Morrison & Hecker LLP
LandOfFree
Antagonists of the magnesium binding defect as therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of the magnesium binding defect as therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of the magnesium binding defect as therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3686633